Vestcor Inc Trims Stock Holdings in Hims & Hers Health, Inc. $HIMS

Vestcor Inc trimmed its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 48.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 21,955 shares of the company’s stock after selling 20,238 shares during the period. Vestcor Inc’s holdings in Hims & Hers Health were worth $713,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of HIMS. Farallon Capital Management LLC grew its stake in Hims & Hers Health by 30.8% in the 3rd quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after buying an additional 2,533,271 shares in the last quarter. Norges Bank bought a new position in Hims & Hers Health in the 4th quarter valued at $62,153,000. Invesco Ltd. boosted its holdings in Hims & Hers Health by 62.7% in the 3rd quarter. Invesco Ltd. now owns 4,152,409 shares of the company’s stock valued at $235,525,000 after purchasing an additional 1,600,004 shares during the period. Clear Street Group Inc. bought a new position in Hims & Hers Health in the 3rd quarter valued at $87,372,000. Finally, Vanguard Group Inc. boosted its holdings in Hims & Hers Health by 7.2% in the 4th quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after purchasing an additional 1,407,651 shares during the period. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Stock Performance

NYSE HIMS opened at $27.08 on Tuesday. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $70.43. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. The company has a market capitalization of $6.27 billion, a P/E ratio of -300.88, a P/E/G ratio of 49.14 and a beta of 2.37. The company has a fifty day moving average of $24.73 and a 200-day moving average of $26.96.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The company had revenue of $608.10 million for the quarter, compared to the consensus estimate of $616.84 million. During the same period in the prior year, the firm posted $0.20 earnings per share. The business’s revenue was up 3.8% on a year-over-year basis. As a group, equities research analysts predict that Hims & Hers Health, Inc. will post 0.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have commented on HIMS shares. Citigroup raised their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a report on Tuesday, May 12th. JPMorgan Chase & Co. cut their price target on shares of Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. BTIG Research reaffirmed a “neutral” rating on shares of Hims & Hers Health in a report on Tuesday, May 12th. Finally, Needham & Company LLC lifted their price objective on shares of Hims & Hers Health from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday, May 12th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat, Hims & Hers Health has an average rating of “Hold” and a consensus price target of $28.70.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 7,950 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $23.64, for a total value of $187,938.00. Following the completion of the sale, the chief financial officer directly owned 262,954 shares of the company’s stock, valued at $6,216,232.56. The trade was a 2.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Michael Chi sold 97,289 shares of the business’s stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $24.69, for a total transaction of $2,402,065.41. Following the completion of the sale, the chief operating officer directly owned 407,282 shares of the company’s stock, valued at $10,055,792.58. This represents a 19.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 212,807 shares of company stock valued at $5,473,644. Company insiders own 11.76% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.